Sepehr Nowfar, MD
Urology · Whittier, CANPI 1124174560
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Teleflex LLC at 45.4% of the total. Reporting peaked in 2023 at $8,615 and has fallen 58.0% since, to $3,620 in 2025.
Across 443 payments — averaging $45.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$9K
- Dendreon Pharmaceuticals LLC$2K
- Janssen Scientific Affairs, LLC$1K
- Coloplast$723
- Sumitomo Pharma America, Inc.$594
- Janssen Global Services, LLC$500
- plus $6K from 54 others
Across 93 payments — averaging $16,694 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$992K
- Bayer$350K
- Sumitomo Pharma America, Inc.$193K
- AbbVie$17K
What the payments were for
- Consulting fees$7,31836%
- Speaking & faculty fees$1,2006%
- Travel & lodging$4932%
- Food & beverage$10,43052%
- Education$6173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$1,100
- UroLift$716
- Barrigel$700
- PROVENGE$202
- TITAN$189
- AquaBeam Robotic System$142
- UroLift System$138
- Prolaris$127
- NEOX$110
- CLARIX$110
How this compares
$20,059 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 26 | $352,188 |
| OrgovyxRelugolix | 46 | $120,076 |
| MyrbetriqMirabegron | 31 | $27,166 |
| Potassium Citrate ErPotassium Citrate | 39 | $6,678 |
| Tamsulosin Hcl | 363 | $5,947 |
| Oxybutynin Chloride ErOxybutynin Chloride | 102 | $4,192 |
| Trospium Chloride ErTrospium Chloride | 16 | $3,842 |
| Estradiol | 57 | $3,178 |
| Silodosin | 26 | $2,831 |
| Finasteride | 172 | $2,374 |
| NitrofurantoinNitrofurantoin Macrocrystal | 54 | $1,752 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $1,499 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 54 | $1,381 |
| Testosterone Cypionate | 18 | $816 |
| Cephalexin | 34 | $205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $295 | $379,35357 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $594 | $120,07646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.
Other urology in Whittier
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
- William AronsonLos Angeles$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.